Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Assessment of KL-6 as a tumor marker in patients with hepatocellular carcinoma
World Journal of Gastroenterology, Volume 11, No. 42, Year 2005
Notification
URL copied to clipboard!
Description
Aim: To investigate the clinical significance of KL-6 as a tumor marker of HCC in two different ethnic groups with chronic liver disease consecutively encountered at outpatient clinics. Methods: Serum KL-6 was measured by the sandwich enzyme immunoassay method using the KL-6 antibody (Ab) as both the capture and tracer Ab according to the manufacturer's instructions (Eisai, Tokyo, Japan). Assessment of alpha fetoprotein (AFP) and protein induced vitamin K deficiency or absence (PIVKA-II) was performed in both groups using commercially available kits. Results: A significantly higher mean serum KL-6 (556±467 U/L) was found in HCC in comparison with non-HCC groups either with (391±176 U/L; P<0.001) or without (361±161 U/L; P<0.001) liver cirrhosis (LC). Serum KL-6 level did not correlate with either AFP or PIVKA-II serU/Levels. Using receiver operating curve analysis for KL-6 as a predictor for HCC showed that the area under the curve was 0.574 (95%CI = 0.50-0.64) and the KL-6 level that gave the best sensitivity (61%) was found to be 334 U/L but according to the manufacturer's instructions; a cut-off point of 500 U/L was used that showed the highest specificity (80%) in comparison with AFP and PIVKA-II (78% vs 72% respectively). Combining the values of the three markers improved specificity of AFP for HCC diagnosis from 78% for AFP alone; 93% for AFP plus PIVKA-II to 99% for both plus KL-6 value (P<0.001). Mean serum alkaline phosphatase level was significantly higher in KL-6 positive (564±475) in comparison with KL-6 negative (505±469) HCC patients (P = 0.021), but such a difference was not found among non-HCC corresponding groups. Conclusion: KL-6 is suggested as a tumor for HCC. Its positivity may reflect HCC-associated cholestasis and/or local tumor invasion. © 2005 The WJG Press and Elsevier Inc. All rights reserved.
Authors & Co-Authors
Gad, Amal A.
Japan, Matsumoto
Shinshu University Faculty of Medicine
Egypt, Ismailia
Faculty of Medicine
Tanaka, Eiji
Japan, Matsumoto
Shinshu University Faculty of Medicine
Matsumoto, Akihiro
Japan, Matsumoto
Shinshu University Faculty of Medicine
Wahab, Matsumoto Abd El
Japan, Matsumoto
Shinshu University Faculty of Medicine
Serwah, Abdel El Hamid Ahmed
Egypt, Ismailia
Faculty of Medicine
Attia, Fawzy
Egypt, Ismailia
Faculty of Medicine
Ali, Khalil
Egypt, Ismailia
Faculty of Medicine
Hassouba, Howayda
Egypt, Ismailia
Faculty of Medicine
El-Deeb, Abd El Raoof
Egypt, Ismailia
Faculty of Medicine
Ichijyo, Tetsuya
Japan, Matsumoto
Shinshu University Faculty of Medicine
Umemura, Takeji
Japan, Matsumoto
Shinshu University Faculty of Medicine
Muto, Hidetomo
Japan, Matsumoto
Shinshu University Faculty of Medicine
Yoshizawa, Kaname
Japan, Matsumoto
Shinshu University Faculty of Medicine
Kiyosawa, Kendo
Japan, Matsumoto
Shinshu University Faculty of Medicine
Japan, Matsumoto
Graduate School of Medicine
Statistics
Citations: 30
Authors: 14
Affiliations: 3
Identifiers
Doi:
10.3748/wjg.v11.i42.6607
ISSN:
10079327
Research Areas
Cancer